Latest Articles and Analysis

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Global Fund report shows COVID-19 reduced HIV/HCV program efficacy while South Africa tripled ART coverage.

Analyzes CMS marketplace rule changes and Medicaid expansion risks as pandemic emergency declarations end.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Analysis of hepatitis B vaccine efficacy and revaccination protocols for people living with HIV.

COVID-19 strains public health efforts addressing HIV outbreaks, diverting resources from the domestic epidemic.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Study explores social-spatial networks and HIV/HCV diagnosis rates among homeless and injection drug users.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

Explores the personal toll of patient advocacy, examining burnout and the need to support advocates.

WHO 2030 HCV elimination goal at risk; only 5 of 110 countries on track as COVID-19 disrupts progress.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

Overview of the 340B Drug Discount Program for patient advocates covering program history and key policy issues.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.